ReviewClinical and experimental medicine2025

Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective.

Negar Sadat Sherafat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.